What is he best known for?
The fields of study he is best known for:
- Cancer
- Internal medicine
- Breast cancer
His primary areas of study are Breast cancer, Internal medicine, Oncology, Cancer and Surgery.
His Breast cancer study integrates concerns from other disciplines, such as Cancer research and Metastasis.
His research investigates the connection with Internal medicine and areas like Gynecology which intersect with concerns in Epidemiology.
His Oncology study incorporates themes from Retrospective cohort study, Pathology, Proportional hazards model, Hazard ratio and Survival analysis.
His study ties his expertise on Odds ratio together with the subject of Cancer.
His Surgery research is multidisciplinary, relying on both Gastroenterology and Disease.
His most cited work include:
- PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients (1523 citations)
- Breast Cancer Molecular Subtypes Respond Differently to Preoperative Chemotherapy (1509 citations)
- Future of Cancer Incidence in the United States: Burdens Upon an Aging, Changing Nation (1133 citations)
What are the main themes of his work throughout his whole career to date?
His main research concerns Internal medicine, Breast cancer, Oncology, Cancer and Chemotherapy.
His Internal medicine study combines topics from a wide range of disciplines, such as Gastroenterology and Surgery.
The various areas that Gabriel N. Hortobagyi examines in his Surgery study include Taxane and Carcinoma.
His Breast cancer research incorporates elements of Cancer research, Pathology, Gynecology, Stage and Radiation therapy.
His work carried out in the field of Oncology brings together such families of science as Neoadjuvant therapy, Clinical trial, Trastuzumab, Anthracycline and Disease.
His studies in Cancer integrate themes in fields like Retrospective cohort study and Hazard ratio.
He most often published in these fields:
- Internal medicine (71.29%)
- Breast cancer (67.35%)
- Oncology (58.83%)
What were the highlights of his more recent work (between 2012-2021)?
- Internal medicine (71.29%)
- Breast cancer (67.35%)
- Oncology (58.83%)
In recent papers he was focusing on the following fields of study:
The scientist’s investigation covers issues in Internal medicine, Breast cancer, Oncology, Cancer and Cancer research.
His Internal medicine study focuses mostly on Chemotherapy, Metastatic breast cancer, Proportional hazards model, Stage and Hazard ratio.
Within one scientific family, Gabriel N. Hortobagyi focuses on topics pertaining to Surgery under Breast cancer, and may sometimes address concerns connected to Adverse effect.
In his study, Capecitabine and Neoadjuvant therapy is inextricably linked to Trastuzumab, which falls within the broad field of Oncology.
The concepts of his Cancer study are interwoven with issues in Placebo, Cohort and Bioinformatics.
His Cancer research research is multidisciplinary, incorporating perspectives in Immune checkpoint, Immunotherapy, Cancer cell, Cancer stem cell and Immunology.
Between 2012 and 2021, his most popular works were:
- Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer (743 citations)
- ESR1 ligand-binding domain mutations in hormone-resistant breast cancer (672 citations)
- Differential response to neoadjuvant chemotherapy among 7 triple-negative breast cancer molecular subtypes (404 citations)
In his most recent research, the most cited papers focused on:
- Cancer
- Internal medicine
- Breast cancer
His primary areas of study are Internal medicine, Breast cancer, Oncology, Cancer and Proportional hazards model.
Gabriel N. Hortobagyi has researched Internal medicine in several fields, including Gynecology and Surgery.
His research integrates issues of Cancer research, Chemotherapy regimen, Survival rate, Retrospective cohort study and Stage in his study of Breast cancer.
His Oncology research incorporates themes from Neoadjuvant therapy, Trastuzumab, Inflammatory breast cancer, Disease and Cohort.
His Cancer research includes themes of Incidence, PARP inhibitor and Bioinformatics.
His study in Chemotherapy is interdisciplinary in nature, drawing from both Taxane and Estrogen receptor.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
